{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:35:47Z","timestamp":1777415747216,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T00:00:00Z","timestamp":1556755200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Janssen Scientific Affairs, LLC","award":["None"],"award-info":[{"award-number":["None"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s10067-019-04543-z","type":"journal-article","created":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T20:02:49Z","timestamp":1556827369000},"page":"2501-2508","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Outcomes of infliximab dose escalation in patients with rheumatoid arthritis"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9226-979X","authenticated-orcid":false,"given":"Stanley B.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel M.","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly J.","family":"Dandreo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George W.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Magner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelly","family":"Kafka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphael J.","family":"DeHoratius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorie","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Parenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,2]]},"reference":[{"key":"4543_CR1","first-page":"1","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St.Clair EW, Tindall E, Miller AS, McAlindon T (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68:1\u201326","journal-title":"Arthritis Rheumatol"},{"key":"4543_CR2","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Po\u00f3r G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960\u2013977","journal-title":"Ann Rheum Dis"},{"key":"4543_CR3","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.3899\/jrheum.140164","volume":"41","author":"GW Cannon","year":"2014","unstructured":"Cannon GW, DuVall SL, Haroldsen CL et al (2014) Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis. J Rheumatol 41:1935\u20131943","journal-title":"J Rheumatol"},{"key":"4543_CR4","volume-title":"PA","author":"Infliximab package insert","year":"2013","unstructured":"Infliximab package insert (2013) Janssen Biotech, Inc., Horsham. In: PA"},{"key":"4543_CR5","first-page":"71","volume":"2","author":"C Plasencia","year":"2015","unstructured":"Plasencia C, Jurado T, Villalba A et al (2015) Effect of infliximab dose increase in rheumatoid arthritis at different trough concentrations: a cohort study in clinical practice conditions. Front Med (Lausanne) 2:71","journal-title":"Front Med (Lausanne)"},{"issue":"Suppl 1","key":"4543_CR6","doi-asserted-by":"publisher","first-page":"i12","DOI":"10.1136\/ard.2010.146852","volume":"70","author":"DE Furst","year":"2011","unstructured":"Furst DE, Keystone EC, Braun J et al (2011) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis 70(Suppl 1):i12\u2013i36","journal-title":"Ann Rheum Dis"},{"key":"4543_CR7","first-page":"1538","volume":"31","author":"R Stern","year":"2004","unstructured":"Stern R, Wolfe F (2004) Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol 31:1538\u20131545","journal-title":"J Rheumatol"},{"key":"4543_CR8","unstructured":"Ellis L, Le C, McDermott JD, Daniel SR (2017) Real-world, multi-site, observational study of infusion time and treatment satisfaction in rheumatoid arthritis patients treated with intravenous golimumab or infliximab [poster PM548]. Poster presented at: 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; May 20\u201324, 2017; Boston, MA"},{"key":"4543_CR9","first-page":"737","volume":"33","author":"RJ Moots","year":"2015","unstructured":"Moots RJ, Mays R, Stephens J, Tarallo M (2015) Burden of dose escalation with tumour necrosis factor inhibitors in rheumatoid arthritis: a systematic review of frequency and costs. Clin Exp Rheumatol 33:737\u2013745","journal-title":"Clin Exp Rheumatol"},{"key":"4543_CR10","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1185\/03007995.2013.786693","volume":"29","author":"MD Fisher","year":"2013","unstructured":"Fisher MD, Watson C, Fox KM, Chen YW, Gandra SR (2013) Dosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care population. Curr Med Res Opin 29:561\u2013568","journal-title":"Curr Med Res Opin"},{"key":"4543_CR11","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1185\/03007995.2012.656844","volume":"28","author":"VF Schabert","year":"2012","unstructured":"Schabert VF, Bruce B, Ferrufino CF, Globe DR, Harrison DJ, Lingala B, Fries JF (2012) Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study. Curr Med Res Opin 28:569\u2013580","journal-title":"Curr Med Res Opin"},{"key":"4543_CR12","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1136\/ard.2008.090860","volume":"68","author":"K Pavelka","year":"2009","unstructured":"Pavelka K, Jarosov\u00e1 K, Such\u00fd D et al (2009) Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. Ann Rheum Dis 68:1285\u20131289","journal-title":"Ann Rheum Dis"},{"key":"4543_CR13","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1136\/ard.2006.065995","volume":"66","author":"MU Rahman","year":"2007","unstructured":"Rahman MU, Strusberg I, Geusens P, Berman A, Yocum D, Baker D, Wagner C, Han J, Westhovens R (2007) Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 66:1233\u20131238","journal-title":"Ann Rheum Dis"},{"key":"4543_CR14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.semarthrit.2013.01.007","volume":"43","author":"G Eng","year":"2013","unstructured":"Eng G, Stoltenberg MB, Szkudlarek M, Bouchelouche PN, Christensen R, Bliddal H, Marie Bartels E (2013) Efficacy of treatment intensification with adalimumab, etanercept and infliximab in rheumatoid arthritis: a systematic review of cohort studies with focus on dose. Semin Arthritis Rheum 43:144\u2013151","journal-title":"Semin Arthritis Rheum"},{"key":"4543_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3111\/13696998.2013.856314","volume":"17","author":"AT Joyce","year":"2014","unstructured":"Joyce AT, Gandra SR, Fox KM, Smith TW, Pill MW (2014) National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-na\u00efve rheumatoid arthritis patients in US health plans. J Med Econ 17:1\u201310","journal-title":"J Med Econ"},{"issue":"Suppl 39","key":"4543_CR16","first-page":"S100","volume":"23","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Smolen J (2005) The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 23(Suppl 39):S100\u2013S108","journal-title":"Clin Exp Rheumatol"},{"key":"4543_CR17","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/acr.21649","volume":"64","author":"J Anderson","year":"2012","unstructured":"Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, Saag KG, O'dell JR, Kazi S (2012) Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res 64:640\u2013647","journal-title":"Arthritis Care Res"},{"key":"4543_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/art.1780230202","volume":"23","author":"JF Fries","year":"1980","unstructured":"Fries JF, Spitz P, Kraines G, Holman H (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23:137\u2013145","journal-title":"Arthritis Rheum"},{"key":"4543_CR19","first-page":"90","volume-title":"Visualizing data","author":"WS Cleveland","year":"1993","unstructured":"Cleveland WS (1993) Bivariate data. In: Cleveland WS (ed) Visualizing data. Hobart Press, New Jersey, pp 90\u2013101"},{"key":"4543_CR20","unstructured":"Newson R (2000) sg151: B\u2013splines and splines parameterized by their values at reference points on the x\u2013axis. Stata Tech Bull 57:20\u201327, Reprinted in Stata Tech Bull Reprints 10:221\u2013230"},{"key":"4543_CR21","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1136\/ard.2011.153023","volume":"70","author":"T Takeuchi","year":"2011","unstructured":"Takeuchi T, Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T, Koike T (2011) Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis 70:1208\u20131215","journal-title":"Ann Rheum Dis"},{"key":"4543_CR22","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1136\/annrheumdis-2012-202591","volume":"72","author":"T Dervieux","year":"2013","unstructured":"Dervieux T, Weinblatt ME, Kivitz A, Kremer JM (2013) Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid arthritis. Ann Rheum Dis 72:908\u2013910","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04543-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-019-04543-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04543-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T23:27:28Z","timestamp":1588289248000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-019-04543-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,2]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["4543"],"URL":"https:\/\/doi.org\/10.1007\/s10067-019-04543-z","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,2]]},"assertion":[{"value":"20 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All study participants provided written informed consent. Institutional Review Board (IRB) approvals for this study were obtained from a central IRB (New England IRB, Needham, Massachusetts, USA; IRB registration number 120160610) for private practice sites and local IRBs of participating academic sites.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Dr. Cohen has served as an investigator and consultant for Amgen, AbbVie, Janssen, Genentech, Pfizer, Merck, Bristol-Myers Squibb, and Roche (less than $10,000 each). Dr. Kremer is employed by and has equity interest in Corrona, LLC, and has served as a consultant for AbbVie, Amgen, Bristol-Myers Squibb, Gilead, GSK, Eli Lilly and Company, Genentech, Medimmune, Sanofi, and Pfizer Inc. (less than $10,000 each) and an investigator for AbbVie, Genentech, Eli Lilly and Company, Novartis, and Pfizer Inc. (less than $10,000 each). Ms. Dandreo is employed by Corrona, LLC. Dr. Reed is employed by and has stock ownership in Corrona, LLC. Mr. Magner is employed by Corrona, LLC. Dr. Shan is employed by Corrona, LLC. Dr. Kafka is employed by and has stock ownership in Johnson and Johnson. Dr. DeHoratius was employed by (at the time the work was conducted) and has stock ownership in Johnson and Johnson. Dr. Ellis is employed by and has stock ownership in Johnson and Johnson. Dr. Parenti was employed by (at the time the work was conducted) and has stock ownership in Johnson and Johnson.The authors have full control of all primary data. Corrona dataset is based on a large US multicenter study adhering to a number of institutional review boards, with complex logistics. Patients did not provide consent to raw data sharing during the data collection for this purpose, and the Corrona data sharing policies do not permit raw data sharing for this purpose. An aggregated limited dataset from the current analyses is available to qualified investigators with an approved protocol. Data requests may be sent to Corrona, represented by Dr. Leslie Harrold, email lharrold@corrona.org.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}